Federal Pharma: Expected to record profit of 2 billion yuan in 2025, with licensing fee income from Novo Nordisk contributing approximately 1.3 billion yuan

LightningPacketLoss

2026-03-18 02:04:11

Abstract generation in progress

Recently, Federal Pharmaceutical announced that it expects to record a profit of approximately 2 billion yuan for the fiscal year ending December 31, 2025, representing a decrease of about 24.76% compared to the profit of approximately 2.658 billion yuan in 2024.

The main reason for the decline in the company’s profit is the decrease in market prices for intermediate products and raw materials within the year, leading to a profit drop of about 1.6 billion yuan and 400 million yuan in these two segments, respectively.

Although the profit from the intermediate products and raw materials segment has decreased, the profit from the formulation products segment has increased significantly by about 1.4 billion yuan, with licensing fee income from Novo Nordisk contributing approximately 1.3 billion yuan, partially offsetting the decline in the intermediate products and raw materials segments.

(Federal Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.